NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Share price
+$15.09 (+153.4%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Nurix Therapeutics, Inc. grew revenue 738.8% to $701.94M over the twelve months to Aug 31, 2026. Free cash flow was $369.81M.
Revenue
$701.94M
+738.8% vs. a year earlier
Operating income
$289.66M
TTM Q3 2026
Free cash flow
$369.81M
TTM Q3 2026
EPS, diluted
$2.31
TTM Q3 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Aug 31, 2026
Valuation
- Market cap
- $2.90B
- P/E ratio
- 10.8
- Price to sales
- 4.13
- Price to book
- 2.99
- Dividend yield
- 0.00%
- Free cash flow yield
- 12.77%
Fundamentals
- Revenue
- $701.94M
- Net income
- $294.88M
- EPS, diluted
- $2.31
- Free cash flow
- $369.81M
- Book value per share
- $8.34
- Diluted shares
- 116M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$701.94M+738.8% YoY
Operating income
$289.66M
Net income
$294.88M
EPS, diluted
$2.31
Free cash flow
$369.81M
Reported periodTrailing twelve months